| Autor: |
Tzar MN; Universiti Kebangsaan Malaysia, Faculty of Medicine, Department of Medical Microbiology and Immunology, Kuala Lumpur, Malaysia. tzar@ppukm.ukm.edu.my., Mustakim S; Hospital Tengku Ampuan Rahimah, Pathology Department, Microbiology Unit, Klang, Selangor, Malaysia., Yusoff H; Universiti Kebangsaan Malaysia, Faculty of Medicine, Department of Medical Microbiology and Immunology, Kuala Lumpur, Malaysia., Tap RM; Institute for Medical Research, Infectious Disease Research Centre, Bacteriology Unit, Jalan Pahang, 50588 Kuala Lumpur, Malaysia. |
| Abstrakt: |
Invasive aspergillosis is the second most common invasive human mycosis but susceptibility data of Aspergillus species is limited. Antifungal treatment of aspergillosis is often done empirically without knowing the true susceptibility. Therefore, we aimed to determine antifungal susceptibility of Aspergillus species isolated from various clinical specimens over a 1-year period. We identified 28 Aspergillus isolates by sequencing the internal transcribed spacer (ITS) and β-tubulin genes and performed antifungal susceptibility testing on these isolates using Sensititre YeastOne. The isolates were identified as Aspergillus niger (60.7%), A. fumigatus (21.4%), A. flavus (10.7%), A. chevalieri (3.6%) and A. tubingensis (3.6%). Based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) Antifungal Clinical Breakpoint for Aspergillus spp., 16/17 (94.1%) A. niger isolates were susceptible to amphotericin B, all six isolates (100%) of A. fumigatus were susceptible to amphotericin B, itraconazole and voriconazole, but only 5/6 (83.3%) A. fumigatus were susceptible to posaconazole. Meanwhile, all three (100%) A. flavus isolates were susceptible to itraconazole. There are no other breakpoints established by the EUCAST for other antifungal-species combinations. In conclusions, Aspergillus niger remains the most commonly isolated species from clinical specimens and Aspergillus isolates at our centre are still largely susceptible to amphotericin B, echinocandins and most azoles. This information is valuable in guiding antifungal therapy in the treatment of aspergillosis. |
